全新《CSCO原发性肝癌诊疗指南》发布 多种策略促规范化治疗

2020-07-19 中国新闻网 中国新闻网

秦叔逵认为,肝癌治疗目前正面临着极大的未被满足的需求。 陈静 摄

最新《CSCO原发性肝癌诊疗指南》发布多种策略促规范化治疗

秦叔逵认为,肝癌治疗目前正面临着极大的未被满足的需求。 陈静 摄

中新网上海7月19日电 (记者 陈静)原发性肝癌是目前中国常见恶性肿瘤之一,在肿瘤致死病因中位居第二。记者19日获悉,中国临床肿瘤学会(以下简称CSCO)正式公布备受瞩目的2020年版《CSCO原发性肝癌诊疗指南》(以下简称“指南”),不仅在肝癌一线和二线治疗领域新增了多个靶向、免疫新药以及联合治疗方案,还增加了肝癌诊疗MDT多学科协作的构成和讨论内容。这意味着,今后,肝癌患者将得到更为规范的诊疗。

此次发布的2020版《指南》吸纳了最新的循证医学的进展,更新创新治疗理念。中国抗癌协会肝癌专业委员会主任委员、复旦大学附属中山医院副院长周俭教授表示,新版《指南》对于提高临床医生诊疗水平,促进原发性肝癌的规范化诊疗具有重要意义。

据悉,CSCO肝癌专家委员会主任委员、南京金陵医院肿瘤中心主任医师秦叔逵教授接受采访时表示,与欧美国家不同,中国肝癌在发病原因、治疗策略等 都具有高度异质性。

中国临床肿瘤学会(以下简称CSCO)正式公布备受瞩目的2020年版《CSCO原发性肝癌诊疗指南》。 陈静 摄

中国临床肿瘤学会(以下简称CSCO)正式公布备受瞩目的2020年版《CSCO原发性肝癌诊疗指南》。 陈静 摄

秦叔逵表示,肝癌起病隐匿,早期诊断非常困难;中国肝癌患者多合并基础肝病,治疗棘手,晚期患者治疗手段有限,预后较差。肝癌在中国早筛率不高,约85%的中国患者就诊时已经处于中、晚期,丧失了最佳的治疗时机。

秦叔逵直言,晚期肝细胞癌患者的中位生存期在10个月左右,5年生存率仅约12%,与欧美或日本等亚洲国家差距显着。广大患者盼望得到更加安全有效的创新治疗手段,以显着改善生存周期和生活质量。

据周俭教授介绍,该版《指南》调整了术后辅助治疗领域的免疫治疗;对介入、放疗和消融领域也有相应的适应症扩展及更新;抗病毒治疗亦在此次更新中有了修订。据秦叔逵教授介绍,免疫治疗副作用小、治疗效果明显是目前全球肿瘤治疗的焦点,联合方案的探索给肝癌患者带来了新希望。

肝癌诊疗临床多学科协作团队(MDT)的构成和讨论内容亦是此次《指南》更新的亮点之一。周俭教授表示,MDT诊疗模式可发挥肝癌诊疗领域相关科室的多学科协作,避免单科诊疗的局限性,有利于选择合理的治疗方法和药物,在要求遵循高级别循证医学证据的同时也考虑患者的个体化差异因素。(完)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1846916, encodeId=82e018469163f, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Oct 28 07:11:50 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691409, encodeId=ccfe169140998, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869a29217831, createdName=windight, createdTime=Fri Jan 01 13:11:50 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804358, encodeId=3903804358ff, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fa2381620, createdName=12314969m72暂无昵称, createdTime=Fri Jul 24 18:43:53 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803894, encodeId=398e803894e8, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200719/5f77e4ab06ba4a3a961b7fd5bc87ecd6/240ecd61e8764caabad2a42e7f8a347b.jpg, createdBy=f7083837184, createdName=一只大大的猪, createdTime=Wed Jul 22 14:13:53 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257496, encodeId=61fe125e49622, content=<a href='/topic/show?id=df433e09082' target=_blank style='color:#2F92EE;'>#原发性肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37090, encryptionId=df433e09082, topicName=原发性肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Tue Jul 21 09:11:50 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803472, encodeId=e4638034e2ec, content=起病隐匿, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/972f8c2f32a64cd28f904bad3945efc9/3d1556a9e54b4781a5f4968d888e5874.jpg, createdBy=5d015401562, createdName=海明明, createdTime=Mon Jul 20 12:53:19 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803416, encodeId=2b6680341693, content=MDT十分重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/11/15/e49614a1570002e06ac6ae3e746f71da.jpg, createdBy=57b32484249, createdName=Dr.Chen6945, createdTime=Mon Jul 20 06:23:53 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803401, encodeId=687f8034018b, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/972f8c2f32a64cd28f904bad3945efc9/3d1556a9e54b4781a5f4968d888e5874.jpg, createdBy=5d015401562, createdName=海明明, createdTime=Mon Jul 20 00:40:16 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803368, encodeId=4579803368bb, content=很好,收获很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200719/5f77e4ab06ba4a3a961b7fd5bc87ecd6/240ecd61e8764caabad2a42e7f8a347b.jpg, createdBy=f7083837184, createdName=1373ce12m31暂无昵称, createdTime=Sun Jul 19 21:38:07 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040304, encodeId=40621040304cf, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sun Jul 19 21:11:50 CST 2020, time=2020-07-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1846916, encodeId=82e018469163f, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Oct 28 07:11:50 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691409, encodeId=ccfe169140998, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869a29217831, createdName=windight, createdTime=Fri Jan 01 13:11:50 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804358, encodeId=3903804358ff, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fa2381620, createdName=12314969m72暂无昵称, createdTime=Fri Jul 24 18:43:53 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803894, encodeId=398e803894e8, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200719/5f77e4ab06ba4a3a961b7fd5bc87ecd6/240ecd61e8764caabad2a42e7f8a347b.jpg, createdBy=f7083837184, createdName=一只大大的猪, createdTime=Wed Jul 22 14:13:53 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257496, encodeId=61fe125e49622, content=<a href='/topic/show?id=df433e09082' target=_blank style='color:#2F92EE;'>#原发性肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37090, encryptionId=df433e09082, topicName=原发性肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Tue Jul 21 09:11:50 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803472, encodeId=e4638034e2ec, content=起病隐匿, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/972f8c2f32a64cd28f904bad3945efc9/3d1556a9e54b4781a5f4968d888e5874.jpg, createdBy=5d015401562, createdName=海明明, createdTime=Mon Jul 20 12:53:19 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803416, encodeId=2b6680341693, content=MDT十分重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/11/15/e49614a1570002e06ac6ae3e746f71da.jpg, createdBy=57b32484249, createdName=Dr.Chen6945, createdTime=Mon Jul 20 06:23:53 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803401, encodeId=687f8034018b, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/972f8c2f32a64cd28f904bad3945efc9/3d1556a9e54b4781a5f4968d888e5874.jpg, createdBy=5d015401562, createdName=海明明, createdTime=Mon Jul 20 00:40:16 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803368, encodeId=4579803368bb, content=很好,收获很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200719/5f77e4ab06ba4a3a961b7fd5bc87ecd6/240ecd61e8764caabad2a42e7f8a347b.jpg, createdBy=f7083837184, createdName=1373ce12m31暂无昵称, createdTime=Sun Jul 19 21:38:07 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040304, encodeId=40621040304cf, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sun Jul 19 21:11:50 CST 2020, time=2020-07-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1846916, encodeId=82e018469163f, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Oct 28 07:11:50 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691409, encodeId=ccfe169140998, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869a29217831, createdName=windight, createdTime=Fri Jan 01 13:11:50 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804358, encodeId=3903804358ff, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fa2381620, createdName=12314969m72暂无昵称, createdTime=Fri Jul 24 18:43:53 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803894, encodeId=398e803894e8, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200719/5f77e4ab06ba4a3a961b7fd5bc87ecd6/240ecd61e8764caabad2a42e7f8a347b.jpg, createdBy=f7083837184, createdName=一只大大的猪, createdTime=Wed Jul 22 14:13:53 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257496, encodeId=61fe125e49622, content=<a href='/topic/show?id=df433e09082' target=_blank style='color:#2F92EE;'>#原发性肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37090, encryptionId=df433e09082, topicName=原发性肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Tue Jul 21 09:11:50 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803472, encodeId=e4638034e2ec, content=起病隐匿, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/972f8c2f32a64cd28f904bad3945efc9/3d1556a9e54b4781a5f4968d888e5874.jpg, createdBy=5d015401562, createdName=海明明, createdTime=Mon Jul 20 12:53:19 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803416, encodeId=2b6680341693, content=MDT十分重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/11/15/e49614a1570002e06ac6ae3e746f71da.jpg, createdBy=57b32484249, createdName=Dr.Chen6945, createdTime=Mon Jul 20 06:23:53 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803401, encodeId=687f8034018b, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/972f8c2f32a64cd28f904bad3945efc9/3d1556a9e54b4781a5f4968d888e5874.jpg, createdBy=5d015401562, createdName=海明明, createdTime=Mon Jul 20 00:40:16 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803368, encodeId=4579803368bb, content=很好,收获很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200719/5f77e4ab06ba4a3a961b7fd5bc87ecd6/240ecd61e8764caabad2a42e7f8a347b.jpg, createdBy=f7083837184, createdName=1373ce12m31暂无昵称, createdTime=Sun Jul 19 21:38:07 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040304, encodeId=40621040304cf, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sun Jul 19 21:11:50 CST 2020, time=2020-07-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1846916, encodeId=82e018469163f, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Oct 28 07:11:50 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691409, encodeId=ccfe169140998, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869a29217831, createdName=windight, createdTime=Fri Jan 01 13:11:50 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804358, encodeId=3903804358ff, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fa2381620, createdName=12314969m72暂无昵称, createdTime=Fri Jul 24 18:43:53 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803894, encodeId=398e803894e8, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200719/5f77e4ab06ba4a3a961b7fd5bc87ecd6/240ecd61e8764caabad2a42e7f8a347b.jpg, createdBy=f7083837184, createdName=一只大大的猪, createdTime=Wed Jul 22 14:13:53 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257496, encodeId=61fe125e49622, content=<a href='/topic/show?id=df433e09082' target=_blank style='color:#2F92EE;'>#原发性肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37090, encryptionId=df433e09082, topicName=原发性肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Tue Jul 21 09:11:50 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803472, encodeId=e4638034e2ec, content=起病隐匿, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/972f8c2f32a64cd28f904bad3945efc9/3d1556a9e54b4781a5f4968d888e5874.jpg, createdBy=5d015401562, createdName=海明明, createdTime=Mon Jul 20 12:53:19 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803416, encodeId=2b6680341693, content=MDT十分重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/11/15/e49614a1570002e06ac6ae3e746f71da.jpg, createdBy=57b32484249, createdName=Dr.Chen6945, createdTime=Mon Jul 20 06:23:53 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803401, encodeId=687f8034018b, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/972f8c2f32a64cd28f904bad3945efc9/3d1556a9e54b4781a5f4968d888e5874.jpg, createdBy=5d015401562, createdName=海明明, createdTime=Mon Jul 20 00:40:16 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803368, encodeId=4579803368bb, content=很好,收获很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200719/5f77e4ab06ba4a3a961b7fd5bc87ecd6/240ecd61e8764caabad2a42e7f8a347b.jpg, createdBy=f7083837184, createdName=1373ce12m31暂无昵称, createdTime=Sun Jul 19 21:38:07 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040304, encodeId=40621040304cf, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sun Jul 19 21:11:50 CST 2020, time=2020-07-19, status=1, ipAttribution=)]
    2020-07-22 一只大大的猪

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1846916, encodeId=82e018469163f, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Oct 28 07:11:50 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691409, encodeId=ccfe169140998, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869a29217831, createdName=windight, createdTime=Fri Jan 01 13:11:50 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804358, encodeId=3903804358ff, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fa2381620, createdName=12314969m72暂无昵称, createdTime=Fri Jul 24 18:43:53 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803894, encodeId=398e803894e8, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200719/5f77e4ab06ba4a3a961b7fd5bc87ecd6/240ecd61e8764caabad2a42e7f8a347b.jpg, createdBy=f7083837184, createdName=一只大大的猪, createdTime=Wed Jul 22 14:13:53 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257496, encodeId=61fe125e49622, content=<a href='/topic/show?id=df433e09082' target=_blank style='color:#2F92EE;'>#原发性肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37090, encryptionId=df433e09082, topicName=原发性肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Tue Jul 21 09:11:50 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803472, encodeId=e4638034e2ec, content=起病隐匿, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/972f8c2f32a64cd28f904bad3945efc9/3d1556a9e54b4781a5f4968d888e5874.jpg, createdBy=5d015401562, createdName=海明明, createdTime=Mon Jul 20 12:53:19 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803416, encodeId=2b6680341693, content=MDT十分重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/11/15/e49614a1570002e06ac6ae3e746f71da.jpg, createdBy=57b32484249, createdName=Dr.Chen6945, createdTime=Mon Jul 20 06:23:53 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803401, encodeId=687f8034018b, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/972f8c2f32a64cd28f904bad3945efc9/3d1556a9e54b4781a5f4968d888e5874.jpg, createdBy=5d015401562, createdName=海明明, createdTime=Mon Jul 20 00:40:16 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803368, encodeId=4579803368bb, content=很好,收获很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200719/5f77e4ab06ba4a3a961b7fd5bc87ecd6/240ecd61e8764caabad2a42e7f8a347b.jpg, createdBy=f7083837184, createdName=1373ce12m31暂无昵称, createdTime=Sun Jul 19 21:38:07 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040304, encodeId=40621040304cf, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sun Jul 19 21:11:50 CST 2020, time=2020-07-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1846916, encodeId=82e018469163f, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Oct 28 07:11:50 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691409, encodeId=ccfe169140998, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869a29217831, createdName=windight, createdTime=Fri Jan 01 13:11:50 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804358, encodeId=3903804358ff, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fa2381620, createdName=12314969m72暂无昵称, createdTime=Fri Jul 24 18:43:53 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803894, encodeId=398e803894e8, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200719/5f77e4ab06ba4a3a961b7fd5bc87ecd6/240ecd61e8764caabad2a42e7f8a347b.jpg, createdBy=f7083837184, createdName=一只大大的猪, createdTime=Wed Jul 22 14:13:53 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257496, encodeId=61fe125e49622, content=<a href='/topic/show?id=df433e09082' target=_blank style='color:#2F92EE;'>#原发性肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37090, encryptionId=df433e09082, topicName=原发性肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Tue Jul 21 09:11:50 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803472, encodeId=e4638034e2ec, content=起病隐匿, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/972f8c2f32a64cd28f904bad3945efc9/3d1556a9e54b4781a5f4968d888e5874.jpg, createdBy=5d015401562, createdName=海明明, createdTime=Mon Jul 20 12:53:19 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803416, encodeId=2b6680341693, content=MDT十分重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/11/15/e49614a1570002e06ac6ae3e746f71da.jpg, createdBy=57b32484249, createdName=Dr.Chen6945, createdTime=Mon Jul 20 06:23:53 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803401, encodeId=687f8034018b, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/972f8c2f32a64cd28f904bad3945efc9/3d1556a9e54b4781a5f4968d888e5874.jpg, createdBy=5d015401562, createdName=海明明, createdTime=Mon Jul 20 00:40:16 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803368, encodeId=4579803368bb, content=很好,收获很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200719/5f77e4ab06ba4a3a961b7fd5bc87ecd6/240ecd61e8764caabad2a42e7f8a347b.jpg, createdBy=f7083837184, createdName=1373ce12m31暂无昵称, createdTime=Sun Jul 19 21:38:07 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040304, encodeId=40621040304cf, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sun Jul 19 21:11:50 CST 2020, time=2020-07-19, status=1, ipAttribution=)]
    2020-07-20 海明明

    起病隐匿

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1846916, encodeId=82e018469163f, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Oct 28 07:11:50 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691409, encodeId=ccfe169140998, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869a29217831, createdName=windight, createdTime=Fri Jan 01 13:11:50 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804358, encodeId=3903804358ff, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fa2381620, createdName=12314969m72暂无昵称, createdTime=Fri Jul 24 18:43:53 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803894, encodeId=398e803894e8, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200719/5f77e4ab06ba4a3a961b7fd5bc87ecd6/240ecd61e8764caabad2a42e7f8a347b.jpg, createdBy=f7083837184, createdName=一只大大的猪, createdTime=Wed Jul 22 14:13:53 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257496, encodeId=61fe125e49622, content=<a href='/topic/show?id=df433e09082' target=_blank style='color:#2F92EE;'>#原发性肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37090, encryptionId=df433e09082, topicName=原发性肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Tue Jul 21 09:11:50 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803472, encodeId=e4638034e2ec, content=起病隐匿, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/972f8c2f32a64cd28f904bad3945efc9/3d1556a9e54b4781a5f4968d888e5874.jpg, createdBy=5d015401562, createdName=海明明, createdTime=Mon Jul 20 12:53:19 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803416, encodeId=2b6680341693, content=MDT十分重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/11/15/e49614a1570002e06ac6ae3e746f71da.jpg, createdBy=57b32484249, createdName=Dr.Chen6945, createdTime=Mon Jul 20 06:23:53 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803401, encodeId=687f8034018b, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/972f8c2f32a64cd28f904bad3945efc9/3d1556a9e54b4781a5f4968d888e5874.jpg, createdBy=5d015401562, createdName=海明明, createdTime=Mon Jul 20 00:40:16 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803368, encodeId=4579803368bb, content=很好,收获很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200719/5f77e4ab06ba4a3a961b7fd5bc87ecd6/240ecd61e8764caabad2a42e7f8a347b.jpg, createdBy=f7083837184, createdName=1373ce12m31暂无昵称, createdTime=Sun Jul 19 21:38:07 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040304, encodeId=40621040304cf, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sun Jul 19 21:11:50 CST 2020, time=2020-07-19, status=1, ipAttribution=)]
    2020-07-20 Dr.Chen6945

    MDT十分重要

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1846916, encodeId=82e018469163f, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Oct 28 07:11:50 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691409, encodeId=ccfe169140998, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869a29217831, createdName=windight, createdTime=Fri Jan 01 13:11:50 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804358, encodeId=3903804358ff, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fa2381620, createdName=12314969m72暂无昵称, createdTime=Fri Jul 24 18:43:53 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803894, encodeId=398e803894e8, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200719/5f77e4ab06ba4a3a961b7fd5bc87ecd6/240ecd61e8764caabad2a42e7f8a347b.jpg, createdBy=f7083837184, createdName=一只大大的猪, createdTime=Wed Jul 22 14:13:53 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257496, encodeId=61fe125e49622, content=<a href='/topic/show?id=df433e09082' target=_blank style='color:#2F92EE;'>#原发性肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37090, encryptionId=df433e09082, topicName=原发性肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Tue Jul 21 09:11:50 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803472, encodeId=e4638034e2ec, content=起病隐匿, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/972f8c2f32a64cd28f904bad3945efc9/3d1556a9e54b4781a5f4968d888e5874.jpg, createdBy=5d015401562, createdName=海明明, createdTime=Mon Jul 20 12:53:19 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803416, encodeId=2b6680341693, content=MDT十分重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/11/15/e49614a1570002e06ac6ae3e746f71da.jpg, createdBy=57b32484249, createdName=Dr.Chen6945, createdTime=Mon Jul 20 06:23:53 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803401, encodeId=687f8034018b, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/972f8c2f32a64cd28f904bad3945efc9/3d1556a9e54b4781a5f4968d888e5874.jpg, createdBy=5d015401562, createdName=海明明, createdTime=Mon Jul 20 00:40:16 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803368, encodeId=4579803368bb, content=很好,收获很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200719/5f77e4ab06ba4a3a961b7fd5bc87ecd6/240ecd61e8764caabad2a42e7f8a347b.jpg, createdBy=f7083837184, createdName=1373ce12m31暂无昵称, createdTime=Sun Jul 19 21:38:07 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040304, encodeId=40621040304cf, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sun Jul 19 21:11:50 CST 2020, time=2020-07-19, status=1, ipAttribution=)]
    2020-07-20 海明明

    挺好

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1846916, encodeId=82e018469163f, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Oct 28 07:11:50 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691409, encodeId=ccfe169140998, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869a29217831, createdName=windight, createdTime=Fri Jan 01 13:11:50 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804358, encodeId=3903804358ff, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fa2381620, createdName=12314969m72暂无昵称, createdTime=Fri Jul 24 18:43:53 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803894, encodeId=398e803894e8, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200719/5f77e4ab06ba4a3a961b7fd5bc87ecd6/240ecd61e8764caabad2a42e7f8a347b.jpg, createdBy=f7083837184, createdName=一只大大的猪, createdTime=Wed Jul 22 14:13:53 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257496, encodeId=61fe125e49622, content=<a href='/topic/show?id=df433e09082' target=_blank style='color:#2F92EE;'>#原发性肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37090, encryptionId=df433e09082, topicName=原发性肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Tue Jul 21 09:11:50 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803472, encodeId=e4638034e2ec, content=起病隐匿, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/972f8c2f32a64cd28f904bad3945efc9/3d1556a9e54b4781a5f4968d888e5874.jpg, createdBy=5d015401562, createdName=海明明, createdTime=Mon Jul 20 12:53:19 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803416, encodeId=2b6680341693, content=MDT十分重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/11/15/e49614a1570002e06ac6ae3e746f71da.jpg, createdBy=57b32484249, createdName=Dr.Chen6945, createdTime=Mon Jul 20 06:23:53 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803401, encodeId=687f8034018b, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/972f8c2f32a64cd28f904bad3945efc9/3d1556a9e54b4781a5f4968d888e5874.jpg, createdBy=5d015401562, createdName=海明明, createdTime=Mon Jul 20 00:40:16 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803368, encodeId=4579803368bb, content=很好,收获很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200719/5f77e4ab06ba4a3a961b7fd5bc87ecd6/240ecd61e8764caabad2a42e7f8a347b.jpg, createdBy=f7083837184, createdName=1373ce12m31暂无昵称, createdTime=Sun Jul 19 21:38:07 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040304, encodeId=40621040304cf, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sun Jul 19 21:11:50 CST 2020, time=2020-07-19, status=1, ipAttribution=)]
    2020-07-19 1373ce12m31暂无昵称

    很好,收获很多

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1846916, encodeId=82e018469163f, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Wed Oct 28 07:11:50 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691409, encodeId=ccfe169140998, content=<a href='/topic/show?id=a6cc90633f2' target=_blank style='color:#2F92EE;'>#规范化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90633, encryptionId=a6cc90633f2, topicName=规范化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=869a29217831, createdName=windight, createdTime=Fri Jan 01 13:11:50 CST 2021, time=2021-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804358, encodeId=3903804358ff, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fa2381620, createdName=12314969m72暂无昵称, createdTime=Fri Jul 24 18:43:53 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803894, encodeId=398e803894e8, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200719/5f77e4ab06ba4a3a961b7fd5bc87ecd6/240ecd61e8764caabad2a42e7f8a347b.jpg, createdBy=f7083837184, createdName=一只大大的猪, createdTime=Wed Jul 22 14:13:53 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257496, encodeId=61fe125e49622, content=<a href='/topic/show?id=df433e09082' target=_blank style='color:#2F92EE;'>#原发性肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37090, encryptionId=df433e09082, topicName=原发性肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Tue Jul 21 09:11:50 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803472, encodeId=e4638034e2ec, content=起病隐匿, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/972f8c2f32a64cd28f904bad3945efc9/3d1556a9e54b4781a5f4968d888e5874.jpg, createdBy=5d015401562, createdName=海明明, createdTime=Mon Jul 20 12:53:19 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803416, encodeId=2b6680341693, content=MDT十分重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/11/15/e49614a1570002e06ac6ae3e746f71da.jpg, createdBy=57b32484249, createdName=Dr.Chen6945, createdTime=Mon Jul 20 06:23:53 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803401, encodeId=687f8034018b, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/972f8c2f32a64cd28f904bad3945efc9/3d1556a9e54b4781a5f4968d888e5874.jpg, createdBy=5d015401562, createdName=海明明, createdTime=Mon Jul 20 00:40:16 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803368, encodeId=4579803368bb, content=很好,收获很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200719/5f77e4ab06ba4a3a961b7fd5bc87ecd6/240ecd61e8764caabad2a42e7f8a347b.jpg, createdBy=f7083837184, createdName=1373ce12m31暂无昵称, createdTime=Sun Jul 19 21:38:07 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040304, encodeId=40621040304cf, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sun Jul 19 21:11:50 CST 2020, time=2020-07-19, status=1, ipAttribution=)]
    2020-07-19 留走人康

    肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负

    0

相关资讯

人到中年怕突然生病,而这个罕见的肿瘤“偏爱”中年人

人到中年,往往上有老人,下有稚子,身边有伴侣,此时最怕生病。而这正是41岁老刘的真实写照。

CELL:肿瘤诊断治疗新策略:代谢检测加饮食治疗

肿瘤的转化与细胞代谢的深刻变化有关,但跟踪这些是否可以改善疾病分层或影响治疗决策,在很大程度上还是未知的。

综述:盘点2020年单细胞测序研究——肿瘤篇

单细胞测序技术自 2009 年问世,2013 年被 Nature Methods 评为年度技术以来,越来越多地被应用在基础科研和临床研究等方面。

Nat Cancer:阻断TNF修正肠道微生物群,可减轻结直肠癌发展

肠道炎症和微生物群是结直肠癌(CRC)病因的两个重要组成部分。然而,目前,我们尚不清楚使用临床相关的抗炎治疗调整炎症是如何影响微生物群的,或者这是否可以影响CRC的结果。

NSR:清华大学朱永法等团队开发新方法:10分钟内消除肿瘤,50天内小鼠存活率从0上升到100%

光催化治疗后50天小鼠存活率从0%增加到100%。基于卟啉的光催化剂由于尺寸选择作用可以被癌细胞靶向地内化而不进入正常细胞。

Nature:线粒体泛醌氧化是肿瘤生长的必要条件

线粒体电子传递链(ETC)对于肿瘤生长是必不可少的,与靶向治疗相结合,ETC的抑制已经被证明有抗肿瘤疗效。此外,人类大脑和肺部肿瘤线粒体具有强大的葡萄糖氧化能力。